{"product_id":"retatrutide-60mg-uae-product","title":"Retatrutide 60mg UAE – Research \u0026 Product Information","description":"\u003cp\u003e\u003c\/p\u003e\u003cp\u003eRetatrutide 60mg UAE is a product listing associated with retatrutide, an investigational compound being studied in clinical research. Retatrutide is also known by the development code LY3437943 and is being investigated as a triple receptor agonist involving the GIP, GLP-1 and glucagon pathways.\u003c\/p\u003e\u003cp\u003eThe compound has attracted substantial scientific interest because researchers are evaluating whether activity across these three receptor systems can influence body weight, metabolic health and other clinical outcomes.\u003c\/p\u003e\u003cp\u003eClinical research on retatrutide has progressed into Phase 3 and Phase 3b studies. Current ClinicalTrials.gov records include studies evaluating weight reduction, maintenance of weight reduction, safety and different dose-escalation approaches.\u003c\/p\u003e\u003cp\u003eThe Pureness X page currently lists a Retatrutide 60 mg product with a displayed price of AED 950. This is the price shown on the online product listing and should not be interpreted as an official UAE medicine price.\u003c\/p\u003e\u003cp\u003e\u003cimg class=\"_resizableImage_1wqvo_111\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/o0roeLeEsdhErrkVPnFLjkNnIvYRZqpxjx9yPvzK.png?v=1788096903\"\u003e\u003c\/p\u003e\u003ch2\u003eWhat Is Retatrutide?\u003c\/h2\u003e\u003cp\u003eRetatrutide, also known as LY3437943, is an investigational compound being developed for metabolic-health research.\u003c\/p\u003e\u003cp\u003eIts distinguishing scientific characteristic is activity across three receptor pathways:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGLP-1 receptor\u003c\/li\u003e\n\u003cli\u003eGIP receptor\u003c\/li\u003e\n\u003cli\u003eGlucagon receptor\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eBecause of this combination, retatrutide is commonly described as a triple agonist.\u003c\/p\u003e\u003cp\u003eThe compound is being studied in clinical trials involving obesity and overweight populations, among other research areas. ClinicalTrials.gov currently lists Phase 3 and Phase 3b retatrutide studies.\u003c\/p\u003e\u003ch2\u003eRetatrutide 60mg UAE Product Information\u003c\/h2\u003e\u003cp\u003eThe Pureness X listing currently identifies this product as Retatrutide 60 mg and displays a price of AED 950.\u003c\/p\u003e\u003ch3\u003eProduct Information\u003c\/h3\u003e\u003cp\u003eInformation\u003c\/p\u003e\u003cp\u003eDetails\u003c\/p\u003e\u003cp\u003eProduct name\u003c\/p\u003e\u003cp\u003eRetatrutide 60 mg\u003c\/p\u003e\u003cp\u003eResearch compound\u003c\/p\u003e\u003cp\u003eRetatrutide\u003c\/p\u003e\u003cp\u003eDevelopment code\u003c\/p\u003e\u003cp\u003eLY3437943\u003c\/p\u003e\u003cp\u003eListed strength\u003c\/p\u003e\u003cp\u003e60 mg\u003c\/p\u003e\u003cp\u003eResearch mechanism\u003c\/p\u003e\u003cp\u003eGLP-1 + GIP + glucagon\u003c\/p\u003e\u003cp\u003eResearch classification\u003c\/p\u003e\u003cp\u003eInvestigational\u003c\/p\u003e\u003cp\u003eListed price\u003c\/p\u003e\u003cp\u003eAED 950\u003c\/p\u003e\u003cp\u003eGeographic topic\u003c\/p\u003e\u003cp\u003eUAE\u003c\/p\u003e\u003cp\u003eThe product-page information above reflects the current online listing and does not establish regulatory approval, clinical equivalence or product authenticity.\u003c\/p\u003e\u003ch2\u003eHow Does the Retatrutide Triple-Agonist Approach Work?\u003c\/h2\u003e\u003cp\u003eRetatrutide is being investigated because it interacts with three hormone-related receptor pathways.\u003c\/p\u003e\u003ch3\u003eGLP-1 Pathway\u003c\/h3\u003e\u003cp\u003eGLP-1 signalling is associated with appetite regulation, satiety and glucose-related physiological processes.\u003c\/p\u003e\u003ch3\u003eGIP Pathway\u003c\/h3\u003e\u003cp\u003eGIP is involved in glucose-dependent insulin signalling and metabolic processes.\u003c\/p\u003e\u003ch3\u003eGlucagon Pathway\u003c\/h3\u003e\u003cp\u003eGlucagon is involved in energy metabolism and regulation of stored energy.\u003c\/p\u003e\u003cp\u003eResearchers are investigating whether combining these three pathways can produce meaningful changes in body weight and metabolic measures.\u003c\/p\u003e\u003cp\u003eThe triple-agonist mechanism is one of the major scientific features that distinguishes retatrutide from compounds acting primarily through a single receptor pathway.\u003c\/p\u003e\u003ch2\u003eRetatrutide Clinical Research\u003c\/h2\u003e\u003cp\u003eRetatrutide has progressed into later-stage clinical development.\u003c\/p\u003e\u003cp\u003eClinicalTrials.gov currently lists several Phase 3 and Phase 3b studies.\u003c\/p\u003e\u003cp\u003eFor example, TRIUMPH-6 is a Phase 3b study examining maintenance of weight reduction in people with obesity.\u003c\/p\u003e\u003cp\u003eTRIUMPH-8 is a Phase 3b study evaluating the efficacy and safety of retatrutide in people with obesity or overweight without type 2 diabetes.\u003c\/p\u003e\u003cp\u003eTRIUMPH-9 is another Phase 3 study examining different dose-escalation approaches in participants with obesity or overweight who do not have type 2 diabetes.\u003c\/p\u003e\u003cp\u003eThere is also a Phase 3 study comparing retatrutide with tirzepatide in adults with obesity.\u003c\/p\u003e\u003cp\u003eThese studies demonstrate ongoing clinical development. They do not mean that retatrutide has already become an approved medicine in every market.\u003c\/p\u003e\u003ch2\u003eRetatrutide and Weight-Loss Research\u003c\/h2\u003e\u003cp\u003eOne of the main areas of retatrutide research is body-weight reduction.\u003c\/p\u003e\u003cp\u003eResearchers are examining:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eChanges in body weight\u003c\/li\u003e\n\u003cli\u003eWeight-maintenance outcomes\u003c\/li\u003e\n\u003cli\u003eMetabolic measurements\u003c\/li\u003e\n\u003cli\u003eSafety and tolerability\u003c\/li\u003e\n\u003cli\u003eDifferences between research groups\u003c\/li\u003e\n\u003cli\u003eLonger-term treatment outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThe scientific purpose of clinical trials is to determine whether observed effects are meaningful, reproducible and sufficiently safe.\u003c\/p\u003e\u003cp\u003eIndividual results cannot be predicted from clinical-trial data alone.\u003c\/p\u003e\u003ch2\u003eRetatrutide vs GLP-1 Research\u003c\/h2\u003e\u003cp\u003eRetatrutide is sometimes discussed alongside GLP-1 medicines because one of its receptor targets is GLP-1.\u003c\/p\u003e\u003cp\u003eHowever, retatrutide is not simply a GLP-1-only compound.\u003c\/p\u003e\u003cp\u003eResearch compound\/type\u003c\/p\u003e\u003cp\u003eReceptor pathways\u003c\/p\u003e\u003cp\u003eGLP-1 agonist\u003c\/p\u003e\u003cp\u003eGLP-1\u003c\/p\u003e\u003cp\u003eGLP-1\/GIP dual agonist\u003c\/p\u003e\u003cp\u003eGLP-1 + GIP\u003c\/p\u003e\u003cp\u003eRetatrutide\u003c\/p\u003e\u003cp\u003eGLP-1 + GIP + glucagon\u003c\/p\u003e\u003cp\u003eThis three-pathway activity is the central scientific feature behind the term triple agonist.\u003c\/p\u003e\u003ch2\u003eWhat Is LY3437943?\u003c\/h2\u003e\u003cp\u003eLY3437943 is the development code associated with retatrutide.\u003c\/p\u003e\u003cp\u003eResearchers and people following clinical development may encounter both terms:\u003c\/p\u003e\u003cp\u003eRetatrutide\u003c\/p\u003e\u003cp\u003eand\u003c\/p\u003e\u003cp\u003eLY3437943\u003c\/p\u003e\u003cp\u003ein clinical-trial records and scientific literature.\u003c\/p\u003e\u003cp\u003eFor example, ClinicalTrials.gov uses “Retatrutide (LY3437943)” in multiple study records.\u003c\/p\u003e\u003cp\u003eThis makes LY3437943 an important secondary research keyword for an informational page.\u003c\/p\u003e\u003ch2\u003eRetatrutide Phase 3 Development\u003c\/h2\u003e\u003cp\u003ePhase 3 research represents a later stage of clinical development.\u003c\/p\u003e\u003cp\u003eCurrent ClinicalTrials.gov records show retatrutide being evaluated in multiple Phase 3 and Phase 3b studies. These studies are examining different populations and outcomes, including weight reduction, weight maintenance and safety.\u003c\/p\u003e\u003cp\u003eThe existence of Phase 3 trials should not be interpreted as proof of regulatory approval.\u003c\/p\u003e\u003cp\u003eClinical development and regulatory authorization are separate processes.\u003c\/p\u003e\u003ch2\u003eRetatrutide UAE Regulatory Status\u003c\/h2\u003e\u003cp\u003eThis section is very important for your UAE SEO page.\u003c\/p\u003e\u003cp\u003eThe Abu Dhabi Department of Health issued Circular No. 40\/2026 on 6 March 2026, warning healthcare facilities, healthcare professionals and the public against an unauthorized medical product identified as “Retatrutide.” The circular states that the product was being promoted online and that retatrutide remained under clinical development, with no authorized supply or legitimate distribution in global markets.\u003c\/p\u003e\u003cp\u003eTherefore, an online listing should not be presented as proof that retatrutide is an approved UAE medicine.\u003c\/p\u003e\u003ch3\u003eImportant distinction\u003c\/h3\u003e\u003cp\u003eOnline product listing ≠ regulatory approval\u003c\/p\u003e\u003cp\u003eClinical trial ≠ medicine authorization\u003c\/p\u003e\u003cp\u003eListed price ≠ official UAE medicine price\u003c\/p\u003e\u003cp\u003eProduct description ≠ proof of authenticity\u003c\/p\u003e\u003cp\u003eThis distinction is particularly important for anyone searching for Retatrutide 60mg UAE.\u003c\/p\u003e\u003ch2\u003eIs Retatrutide Approved in the UAE?\u003c\/h2\u003e\u003cp\u003eBased on the March 2026 Abu Dhabi Department of Health circular, retatrutide was identified as an unauthorized medical product and the authority warned against its use. The circular states that retatrutide remains under clinical development.\u003c\/p\u003e\u003cp\u003eFor this reason, this product page should not claim that retatrutide is an approved UAE weight-loss medicine or routinely available through UAE pharmacies.\u003c\/p\u003e\u003ch2\u003eWhat Should Be Checked When Researching a Peptide Product?\u003c\/h2\u003e\u003cp\u003ePeople researching an online product listing should independently verify relevant information.\u003c\/p\u003e\u003cp\u003eImportant areas include:\u003c\/p\u003e\u003ch3\u003eProduct identity\u003c\/h3\u003e\u003cp\u003eConfirm the stated compound and strength.\u003c\/p\u003e\u003ch3\u003eBatch information\u003c\/h3\u003e\u003cp\u003eCheck whether a specific batch or lot number is provided.\u003c\/p\u003e\u003ch3\u003eLaboratory documentation\u003c\/h3\u003e\u003cp\u003eReview available laboratory documentation and determine exactly what was tested.\u003c\/p\u003e\u003ch3\u003eCertificate of Analysis\u003c\/h3\u003e\u003cp\u003eWhere a COA is provided, check whether it relates to the actual batch.\u003c\/p\u003e\u003ch3\u003eSupplier information\u003c\/h3\u003e\u003cp\u003eVerify the identity and provenance of the supplier.\u003c\/p\u003e\u003ch3\u003eRegulatory status\u003c\/h3\u003e\u003cp\u003eCheck the latest requirements and warnings from the relevant UAE authority.\u003c\/p\u003e\u003ch3\u003eIntended use\u003c\/h3\u003e\u003cp\u003eDo not automatically assume that an online research-product listing is equivalent to an approved pharmaceutical product.\u003c\/p\u003e\u003ch2\u003eRetatrutide 60mg Price in UAE\u003c\/h2\u003e\u003cp\u003eThe current Pureness X product page displays AED 950 for Retatrutide 60 mg.\u003c\/p\u003e\u003cp\u003eFor SEO purposes, it is reasonable to provide the current listed price, but it should be described as an online listing price rather than an official regulated medicine price.\u003c\/p\u003e\u003cp\u003eIf the Shopify price changes later, remember to update the text if you have manually mentioned AED 950 inside the description.\u003c\/p\u003e\u003ch2\u003eRetatrutide Safety Research\u003c\/h2\u003e\u003cp\u003eSafety evaluation remains an important component of retatrutide clinical development.\u003c\/p\u003e\u003cp\u003eClinical studies examine both potential effects and adverse events while monitoring participants under defined research protocols.\u003c\/p\u003e\u003cp\u003eResearch questions can include:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eOverall tolerability\u003c\/li\u003e\n\u003cli\u003eGastrointestinal adverse events\u003c\/li\u003e\n\u003cli\u003eMetabolic measurements\u003c\/li\u003e\n\u003cli\u003eCardiovascular outcomes\u003c\/li\u003e\n\u003cli\u003eTreatment discontinuation\u003c\/li\u003e\n\u003cli\u003eLonger-term safety\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eBecause retatrutide remains investigational, research findings should not be converted into individual medical recommendations.\u003c\/p\u003e\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\u003ch3\u003eWhat is Retatrutide 60mg?\u003c\/h3\u003e\u003cp\u003eRetatrutide is an investigational compound also known as LY3437943. The Pureness X page currently lists a product identified as Retatrutide 60 mg.\u003c\/p\u003e\u003ch3\u003eWhat is LY3437943?\u003c\/h3\u003e\u003cp\u003eLY3437943 is the development code associated with retatrutide and is used in clinical research records.\u003c\/p\u003e\u003ch3\u003eWhat does triple agonist mean?\u003c\/h3\u003e\u003cp\u003eIt refers to retatrutide's investigation across three receptor pathways: GLP-1, GIP and glucagon.\u003c\/p\u003e\u003ch3\u003eIs retatrutide approved in the UAE?\u003c\/h3\u003e\u003cp\u003eThe Abu Dhabi Department of Health issued a March 2026 warning identifying retatrutide as an unauthorized medical product and stating that it remains under clinical development.\u003c\/p\u003e\u003ch3\u003eWhat is the listed price of Retatrutide 60mg UAE?\u003c\/h3\u003e\u003cp\u003eThe Pureness X page currently displays AED 950. This is an online listing price, not an official regulated UAE medicine price.\u003c\/p\u003e\u003ch3\u003eIs retatrutide a GLP-1-only compound?\u003c\/h3\u003e\u003cp\u003eNo. Retatrutide is being investigated as a triple agonist involving GLP-1, GIP and glucagon pathways.\u003c\/p\u003e\u003ch3\u003eIs Retatrutide in Phase 3?\u003c\/h3\u003e\u003cp\u003eYes. Current ClinicalTrials.gov records show Phase 3 and Phase 3b retatrutide studies.\u003c\/p\u003e\u003ch2\u003eResearch \u0026amp; Regulatory Disclaimer\u003c\/h2\u003e\u003cp\u003eThis content is provided for educational and research-information purposes only.\u003c\/p\u003e\u003cp\u003eRetatrutide remains an investigational compound and should not be represented as an approved UAE medicine.\u003c\/p\u003e\u003cp\u003eThis page does not provide individualized medical advice, dosing instructions, injection instructions or treatment recommendations.\u003c\/p\u003e\u003cp\u003eAn online product listing does not establish regulatory approval, authenticity, purity, safety or suitability for human use.\u003c\/p\u003e\u003cp\u003eAlways verify current UAE regulatory information and consult a qualified healthcare professional for medical questions.\u003c\/p\u003e","brand":"Pharma Testostrone","offers":[{"title":"Default Title","offer_id":44629830205528,"sku":null,"price":950.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/Retatrutide_60mg_UAE_research_product.jpg?v=1787244920","url":"https:\/\/timewell.store\/products\/retatrutide-60mg-uae-product","provider":"Timewell","version":"1.0","type":"link"}